Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subject Index

Subject Index JOURNAL OF THORACIC ONCOLOGy Comorbidity, S43 Fluorescent in situ hybridization (FISH), S7, S38 Companion diagnostic, S26 Folate, S26 A protease inhibitor of CD13, S31 Companion imaging agent, S23 Folate Receptor, S22 A549 cell line, S12, S13 Comparative effectiveness research, S31 Free-circulating DNA, S19 Accelerated hyperfractionation, S36 Comprehensive Histologic Assessment, S7 Gefitinib, S38, S42 Adenocarcinoma, S8 Computed tomography S14, S27 Adherence, S43 Cost-effectiveness, S16 Adjuvant chemotherapy, S31, S32 CT imaging, S27 Adjuvant immunotherapy, S31 γ-Fe2O3-NC, S13 CT-guided biopsy, S27 Adriamycin, S29 Gemcitabine, S20, S46 ctr1, S22 Advanced non small cell lung cancer, S47 Gene E, S24 Curcumin, S22 Afatinib, S41 Gene expression analysis, S10 Customized therapy, S36 Akt, S12 Gene expression signatures, S32 Cyclooxygenase 2 (COX-2), S11 ALK gene, S7 Gene rearrangement, S9, S33 Cyclophosphamide, S29 anaplastic lymphoma kinase (ALK) S9, S33 Gene therapy, S25 Cytolysin, S12 Awareness program, S18 Genetic alterations, S7 Genome wide association study, S32 Genomic profile, S38 Germ cell tumor, S52 Darbepoetin alfa, S48 BCL3, S23 GLOBOCAN, S17 Death-associated protein kinase (DAPK), S24 Benign lesions, S9 Disease progression, S28 Benzo (a) pyrene, S13 Dose adjustment, S31 Beta-glucan, S40 DOX, S13 Hedgehog, S51 Bevacizumab, S29, S47, S49 Drug screening, S21 High hydrostatic pressure, S23 Biomarkers, S24 Histology, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/subject-index-nm1Thpct9B

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

JOURNAL OF THORACIC ONCOLOGy Comorbidity, S43 Fluorescent in situ hybridization (FISH), S7, S38 Companion diagnostic, S26 Folate, S26 A protease inhibitor of CD13, S31 Companion imaging agent, S23 Folate Receptor, S22 A549 cell line, S12, S13 Comparative effectiveness research, S31 Free-circulating DNA, S19 Accelerated hyperfractionation, S36 Comprehensive Histologic Assessment, S7 Gefitinib, S38, S42 Adenocarcinoma, S8 Computed tomography S14, S27 Adherence, S43 Cost-effectiveness, S16 Adjuvant chemotherapy, S31, S32 CT imaging, S27 Adjuvant immunotherapy, S31 γ-Fe2O3-NC, S13 CT-guided biopsy, S27 Adriamycin, S29 Gemcitabine, S20, S46 ctr1, S22 Advanced non small cell lung cancer, S47 Gene E, S24 Curcumin, S22 Afatinib, S41 Gene expression analysis, S10 Customized therapy, S36 Akt, S12 Gene expression signatures, S32 Cyclooxygenase 2 (COX-2), S11 ALK gene, S7 Gene rearrangement, S9, S33 Cyclophosphamide, S29 anaplastic lymphoma kinase (ALK) S9, S33 Gene therapy, S25 Cytolysin, S12 Awareness program, S18 Genetic alterations, S7 Genome wide association study, S32 Genomic profile, S38 Germ cell tumor, S52 Darbepoetin alfa, S48 BCL3, S23 GLOBOCAN, S17 Death-associated protein kinase (DAPK), S24 Benign lesions, S9 Disease progression, S28 Benzo (a) pyrene, S13 Dose adjustment, S31 Beta-glucan, S40 DOX, S13 Hedgehog, S51 Bevacizumab, S29, S47, S49 Drug screening, S21 High hydrostatic pressure, S23 Biomarkers, S24 Histology,

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Apr 1, 2014

There are no references for this article.